The lack of biological markers is a critical roadblock in the development of disease-modifying therapeutics for Parkinson's and Alzheimer's disease. The Harvard NeuroDiscovery Biomarker Core is a biomarker incubator designed to overcome this roadblock.
The core is a longitudinal case-control study of over 2,700 individuals with early-stage PD, MCI/AD, and controls without neurologic disease. High-quality biospecimens and high-resolution clinical phenotypes are tracked annually for several years.
A major aim of the program is to provide data and bio-specimens to other investigators engaged in biomarker discovery and development.
Harnessing the power of collaboration: The Harvard Biomarker Core is helping scientists nationwide to develop new biomarkers
Co-director Clemens Scherzer explaining the importance of biomarker discovery.